AVITA Medical's RECELL Platform Achieves Recognition
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) has made significant strides in the field of acute wound care. Their innovative RECELL platform has recently been celebrated as the “Best New Technology Solution – Surgical” during the prestigious 2025 MedTech Breakthrough Awards. This accolade reflects the impact of the RECELL System in transforming wound management and patient care.
Key Features of the RECELL Technology
The RECELL platform utilizes ground-breaking technology for treating thermal burn wounds and full-thickness skin defects. With over 30,000 patients benefiting from its application worldwide, RECELL innovates the conventional methods of wound healing. Unlike traditional grafting, which necessitates larger donor skin areas, RECELL minimizes the amount of donor skin needed. This leads to reduced pain, quicker recoveries, and overall improved patient conditions.
How RECELL Works
RECELL operates by harnessing the unique healing properties of a patient’s skin. The system creates Spray-On Skin Cells, which can be applied directly to the wound site, accelerating the healing process and improving outcomes. Patients experience fewer procedures, better functional and aesthetic results, and shorter stays in medical facilities.
Introducing RECELL GO
The recent introduction of RECELL GO has elevated the technology even further. By enhancing procedural consistency and facilitating greater coordination among surgical teams, RECELL GO ensures that physicians remain central to the healing process. This advancement is particularly beneficial in busy burn and trauma centers, allowing for broader, more efficient use in acute wound care settings.
Leadership Acknowledgment and Future Commitment
Jim Corbett, Chief Executive Officer of AVITA Medical, expressed gratitude for this recognition, emphasizing the platform's advantages in burn and trauma care. He stated, “By requiring significantly less donor skin than traditional grafting, RECELL reduces donor-site pain, accelerates healing, and improves patient outcomes. We remain committed to expanding access and advancing care for patients.”
Further Awards and Recognition
In addition to the honor received for the RECELL platform, AVITA Medical’s Dr. Katie Bush was awarded the 2025 Emerald Pinnacle Healthcare Award in the Medical Device category. This recognition underscores the commitment of AVITA Medical to innovation, leadership, and impactful solutions in healthcare.
About AVITA Medical, Inc.
AVITA Medical is more than just a leading company in acute wound care; it is a pioneer offering transformative solutions. The flagship RECELL System is FDA-approved specifically for treating thermal burn wounds and full-thickness skin defects. This remarkable system not only represents the future of healing but also embodies AVITA Medical's dedication to enhancing recovery times for patients.
In the U.S., AVITA also possesses exclusive rights to manufacture and distribute PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix branded by AVITA Medical. These advancements reflect their unwavering commitment to improving patient care through innovative technologies.
International Standards and Approvals
Outside of the U.S., the RECELL System is recognized for its capability to promote skin healing across various applications, including wounds caused by burns and skin defects. The system is TGA-registered in Australia, has received CE mark approval in Europe, and enjoys PMDA approval in Japan, showcasing its international appeal and efficacy.
Frequently Asked Questions
What is the RECELL platform?
The RECELL platform by AVITA Medical is an innovative skin treatment system that utilizes a patient's own skin to create Spray-On Skin Cells for wound healing.
What recognition did AVITA Medical receive?
AVITA Medical was awarded the “Best New Technology Solution – Surgical” at the 2025 MedTech Breakthrough Awards for the RECELL platform.
How does RECELL improve patient outcomes?
RECELL reduces the amount of donor skin needed compared to traditional grafting, leading to less pain, faster recovery, and better functional results for patients.
Who is the CEO of AVITA Medical?
Jim Corbett serves as the Chief Executive Officer of AVITA Medical, advocating for the continuous advancement of patient care through innovative solutions.
What other products does AVITA Medical offer?
In addition to RECELL, AVITA Medical offers PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix designed to improve wound healing.
